Clinical Trial Update: Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intratumoral/intralesional OBP-301 (an oncolytic virus) for metastatic melanoma to assess efficacy and immunological response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OBP-301

Snippet

Sponsor: Syneos Health | Conditions: Melanoma Stage III, Melanoma Stage Iv | Phase 2 | Status: UNKNOWN